Company profile
PALATIN TECHNOLOGIES INC
NASDAQ:PTNBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PL-3994 | phase2 | — | 1 | withdrawn |
| PL-8177 | phase2 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02333071 | phase3 | completed | 2014-12-01 | 2016-07-01 | Palatin Technologies, Inc | 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder |
| NCT02338960 | phase3 | completed | 2015-01-01 | 2016-08-01 | Palatin Technologies, Inc | 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder |
| NCT06565611 | phase2 | active_not_recruiting | 2024-08-05 | 2025-02-05 | Palatin Technologies, Inc | A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity |
| NCT05201170 | phase3 | completed | 2021-12-30 | 2023-09-01 | Palatin Technologies, Inc | A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye |
| NCT05709444 | phase2 | completed | 2022-12-26 | 2024-04-26 | Palatin Technologies, Inc | A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 103928 | BLA | Palatin Technologies, Inc. | ||||
Loading… | ||||||